Please use this identifier to cite or link to this item: https://doi.org/10.1007/s10495-013-0935-2
Title: Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis
Authors: Murphy, A.C
Weyhenmeyer, B
Noonan, J
Kilbride, S.M
Schimansky, S
Loh, K.P 
Kögel, D
Letai, A.G
Prehn, J.H.M
Murphy, B.M
Keywords: actin
caspase 3
caspase 8
FLICE inhibitory protein
procaspase 3
procaspase 8
protein Bid
protein mcl 1
protein Noxa
roscovitine
tumor necrosis factor related apoptosis inducing ligand
antineoplastic agent
caspase 3
caspase 8
MCL1 protein, human
myeloid leukemia factor 1
PMAIP1 protein, human
protein bcl 2
purine derivative
tumor necrosis factor related apoptosis inducing ligand
apoptosis
article
cell viability assay
controlled study
disease resistance
down regulation
enzyme activation
gene silencing
glioblastoma
glioma cell
human
human cell
human cell culture
neuromodulation
priority journal
protein expression
protein targeting
Brain Neoplasms
drug effects
drug potentiation
drug resistance
genetics
glioblastoma
metabolism
pathology
tumor cell line
Antineoplastic Agents
Apoptosis
Brain Neoplasms
Caspase 3
Caspase 8
Cell Line, Tumor
Drug Resistance, Neoplasm
Drug Synergism
Enzyme Activation
Gene Silencing
Glioblastoma
Humans
Myeloid Cell Leukemia Sequence 1 Protein
Proto-Oncogene Proteins c-bcl-2
Purines
TNF-Related Apoptosis-Inducing Ligand
Issue Date: 2014
Publisher: Kluwer Academic Publishers
Citation: Murphy, A.C, Weyhenmeyer, B, Noonan, J, Kilbride, S.M, Schimansky, S, Loh, K.P, Kögel, D, Letai, A.G, Prehn, J.H.M, Murphy, B.M (2014). Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis 19 (4) : 629-642. ScholarBank@NUS Repository. https://doi.org/10.1007/s10495-013-0935-2
Rights: Attribution 4.0 International
Abstract: Glioblastoma (GBM) is the most aggressive form of primary brain tumour, with dismal patient outcome. Treatment failure is associated with intrinsic or acquired apoptosis resistance and the presence of a highly tumourigenic subpopulation of cancer cells called GBM stem cells. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as a promising novel therapy for some treatment-resistant tumours but unfortunately GBM can be completely resistant to TRAIL monotherapy. In this study, we identified Mcl-1, an anti-apoptotic Bcl-2 family member, as a critical player involved in determining the sensitivity of GBM to TRAIL-induced apoptosis. Effective targeting of Mcl-1 in TRAIL resistant GBM cells, either by gene silencing technology or by treatment with R-roscovitine, a cyclin-dependent kinase inhibitor that targets Mcl-1, was demonstrated to augment sensitivity to TRAIL, both within GBM cells grown as monolayers and in a 3D tumour model. Finally, we highlight that two separate pathways are activated during the apoptotic death of GBM cells treated with a combination of TRAIL and R-roscovitine, one which leads to caspase-8 and caspase-3 activation and a second pathway, involving a Mcl-1:Noxa axis. In conclusion, our study demonstrates that R-roscovitine in combination with TRAIL presents a promising novel strategy to trigger cell death pathways in glioblastoma. © 2013 The Author(s).
Source Title: Apoptosis
URI: https://scholarbank.nus.edu.sg/handle/10635/180765
ISSN: 1360-8185
DOI: 10.1007/s10495-013-0935-2
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1007_s10495-013-0935-2.pdf1.67 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

36
checked on Jan 20, 2021

Page view(s)

22
checked on Jan 21, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons